aRoche S.A., Neuilly-sur-Seine bDepartment of Epidemiological Domestic Surveys, Kantar Health, Paris, France.
Eur J Cancer Prev. 2011 Jan;20 Suppl 1:S5-7. doi: 10.1097/01.cej.0000391561.10889.28.
In France, mass screening for breast and colon cancer issupported by the French National Cancer Institute (INCa). In these nationwide screening campaigns, individuals aged between 50 and 74 years receive a personalized letter inviting them for a screening examination every 2 years. Prostate cancer screening is, however, still controversial and has not been included in the INCa recommendations so far. Research organizations are particularly interested in screening and indeed, several studies have been conducted in France and other countries to examine the different aspects of the subject. To provide actual benefits, screening should be undertaken on a regular scheduled basis. Therefore, several studies have assessed the factors influencing the participation rate of women in breast cancer screening in France (). The Institut National de Prévention et d'Education pour la Santé conducted one of these in 2005: the Baromètre Cancer (including 4046 individuals aged 15 years or older, interviewed by telephone) analysed beliefs and perceptions about cancer screening and studied attendance rates for breast, colon and prostate cancer (including scheduled screening). No previous survey has ever been conducted simultaneously among the general population and physicians with regard to individual and scheduled screening for breast cancer and colorectal cancer (CRC) or individual screening for prostate cancer. EDIFICE is thus the first large-scale survey to assess screening practices in France by analysing the targeted population on the one hand and the clinical practice of French general practitioners (GPs) on the other hand, using the 'mirror study' method to compare results. Two national surveys were conducted in 2005 and 2008. In 2005, only 22 geographical regions were included in the screening programme for CRC.
在法国,国家癌症研究所(INCa)支持对乳腺癌和结肠癌进行大规模筛查。在这些全国性的筛查活动中,年龄在 50 至 74 岁之间的个人会收到个性化的信件,邀请他们每两年进行一次筛查检查。然而,前列腺癌筛查仍存在争议,迄今为止尚未被纳入 INCa 的建议中。研究机构对筛查特别感兴趣,事实上,法国和其他国家已经进行了几项研究来研究该主题的不同方面。为了提供实际效益,筛查应该定期进行。因此,几项研究评估了影响法国女性参与乳腺癌筛查的因素()。国家预防和健康教育研究所于 2005 年进行了其中一项研究:Baromètre Cancer(包括 4046 名年龄在 15 岁或以上的个人,通过电话进行访谈)分析了对癌症筛查的信念和看法,并研究了乳腺癌、结肠癌和前列腺癌(包括计划筛查)的参与率()。以前从未对一般人群和医生同时进行过关于乳腺癌和结直肠癌(CRC)的个体和计划筛查或前列腺癌的个体筛查的调查。因此,EDIFICE 是第一项通过分析目标人群和法国全科医生(GP)的临床实践来评估法国筛查实践的大规模调查,使用“镜像研究”方法来比较结果。2005 年和 2008 年进行了两次全国性调查。2005 年,只有 22 个地理区域被纳入 CRC 筛查计划。